Is there still room for pioglitazone in contemporary type 2 diabetes management? - PubMed
6 hours ago
- #pioglitazone
- #type 2 diabetes
- #GLP-1RA
- Recent real-world evidence shows comparable cardiovascular and hepatic outcomes between GLP-1RA and pioglitazone in type 2 diabetes, with GLP-1RA users having a lower risk of heart failure.
- Pioglitazone retains clinical relevance due to its glycaemic efficacy, potential cardio-hepatic benefits, and low cost, especially in health-care systems with limited access to newer agents.
- Pioglitazone and GLP-1RA are complementary within the current therapeutic landscape, emphasizing the need for individualized treatment selection.
- Contemporary guidelines increasingly prioritize therapies with cardiometabolic benefits, restricting pioglitazone to selected settings despite its recognized adverse effects.